Shares of UnitedHealth Group Inc (NYSE:UNH) ended Friday session in green amid volatile trading. The shares closed up +1.68 points or 1.21% at $140.00 with 4,164,080 shares getting traded. Post opening the session at $139.18, the shares hit an intraday low of $138.42 and an intraday high of $140.48 and the price vacillated in this range throughout the day. The company has a market cap of $134.95 billion and the numbers of outstanding shares have been calculated to be 952.39 million shares.
On September 29, 2016 The University of California and UnitedHealth Group (UNH) are establishing an innovative model for a collaborative approach to health care that will improve patient care for Californians.
The 10-year strategic relationship will help transition California to a value-based health care system while leveraging the expertise of each organization to examine broader trends in care delivery.
UC Health and UnitedHealth Group’s Optum and UnitedHealthcare businesses will promote advancements in clinical research and collectively design patient-centered, clinically integrated care provider networks, with a goal of transforming the state’s health care delivery system. UC Health’s five academic medical centers will expand use of Optum’s clinically integrated network services and advanced data analytics services.
As a cornerstone of the new strategic relationship, UC Health will become the first West Coast health care provider to partner with OptumLabs, an open, collaborative center for research and innovation focused on improving patient care and value. Founded jointly by Optum and Mayo Clinic in 2013, OptumLabs is opening a San Francisco Bay Area facility mirroring its innovative headquarters in Cambridge, Mass., to accelerate collaboration among UC Health and other constituents in the region.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) ended Friday session in green amid volatile trading. The shares closed up +0.36 points or 2.03% at $18.13. Post opening the session at $17.82, the shares hit an intraday low of $17.64 and an intraday high of $18.32 and the price vacillated in this range throughout the day. The company has a market cap of $2.92 billion and the numbers of outstanding shares have been calculated to be 160.90 million shares.
Horizon Pharma PLC (HZNP) on Sept. 29, 2016 announced that it has entered into a rebate agreement with Prime Therapeutics, which secures formulary status for its primary care medicines. The rebate agreement begins on October 1, 2016.
“Our philosophy is and will continue to be to ensure that patients have access to the medicines their physicians prescribe,” said Timothy P. Walbert, chairman, president and chief executive officer. “The Prime Therapeutics rebate agreement in addition to the previously announced CVS/Caremark agreement provides increased access to patients as well as sustainability and durability for our primary care business. We continue discussions and negotiations with other pharmacy benefit managers and payers with the goal of further increasing patient access for our clinically relevant primary care medicines.”